Bristol Myers Squibb Company $BMY Shares Sold by Danske Bank A S

Danske Bank A S lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 23.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,221,703 shares of the biopharmaceutical company’s stock after selling 365,674 shares during the period. Danske Bank A S’s holdings in Bristol Myers Squibb were worth $65,899,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb in the second quarter valued at $25,000. Physician Wealth Advisors Inc. boosted its stake in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb in the fourth quarter valued at $32,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Bristol Myers Squibb during the third quarter worth about $35,000. Finally, JPL Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the third quarter worth about $36,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $58.24 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company has a market cap of $118.92 billion, a P/E ratio of 16.88, a PEG ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a 50-day moving average price of $59.56 and a 200 day moving average price of $54.48.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 66.57%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.27 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were given a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company reiterated an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. UBS Group reiterated a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. Leerink Partners increased their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Finally, Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $61.31.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is currently owned by insiders.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY posted a Q1 beat — $1.58 EPS vs. consensus ~$1.42 and $11.49B revenue — driven by growth drugs and Eliquis outperformance, which supports near‑term cash flow. Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales
• Positive Sentiment: Management reiterated FY outlook and emphasized the “growth portfolio” (Breyanzi, Camzyos) and cost‑cutting progress as drivers of durable margin improvement. Bristol-Myers Squibb Signals Confident Path After Q1 Call
• Positive Sentiment: Pipeline catalysts could lift long‑term growth: Phase III readouts for milvexian (potential Eliquis successor) and Cobenfy (schizophrenia) are highlighted as multi‑year drivers. BMS brings the buzz around late-stage readouts amid a so-so Q1
• Neutral Sentiment: Analysts’ consensus price target sits near $61.31, indicating limited upside from current levels absent new positive catalysts. Bristol Myers Squibb Company (NYSE:BMY) Receives $61.31 Consensus PT from Analysts
• Negative Sentiment: FY 2026 guidance (EPS 6.05–6.35; revenue $46.0–47.5B) left the revenue midpoint slightly below the Street, tempering upside after the quarter and contributing to profit‑taking. Bristol Myers Squibb Reports First Quarter Financial Results for 2026
• Negative Sentiment: Analysts/coverage notes emphasize the scale of the Eliquis patent cliff (multi‑billion dollar risk over coming years), which pressures valuation beyond near‑term beats. Thinning revenues: inside the $14bn Eliquis patent cliff
• Negative Sentiment: Bernstein maintained a Hold rating, signaling that some investors and analysts want clearer evidence that growth and pipeline will offset legacy declines. Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.